E-LIB Suche - Ergebnisse für: Langley, Richard G

1

Bimekizumab Continuous Maintenance of Eesponse at Every Vis..:

Blauvelt, Andrew ; Conrad, Curdin ; Costanzo, Antonio...
SKIN The Journal of Cutaneous Medicine. 8 (2024) 1 - p. s303 , 2024

Link: https://doi.org/10.25251..

2

551 - Continuous tralokinumab treatment over 4 years in adu..:

Blauvelt, Andrew ; Langley, Richard G ; Peris, Ketty...
British Journal of Dermatology. 190 (2024) Supplement_2 - p. ii48-ii49 , 2024

Link: https://doi.org/10.1093/..

3

Bimekizumab Efficacy Through 3 Years in Patients with Moder..:

Lebwohl, Mark ; Strober, Bruce ; Foley, Peter...
SKIN The Journal of Cutaneous Medicine. 8 (2024) 1 - p. s307 , 2024

Link: https://doi.org/10.25251..

4

555 - Safety of tralokinumab for the treatment of atopic de..:

Reich, Kristian ; Langley, Richard G ; Silvestre, Juan Francisco...
British Journal of Dermatology. 190 (2024) Supplement_2 - p. ii52-ii53 , 2024

Link: https://doi.org/10.1093/..

5

Bimekizumab 3-year Safety and Tolerability in Moderate to S..:

Lebwohl, Mark ; Strober, Bruce ; Langley, Richard G....
SKIN The Journal of Cutaneous Medicine. 8 (2024) 1 - p. s305 , 2024

Link: https://doi.org/10.25251..

6

Residual Lesional Gene Expression in Psoriasis Patients wit..:

Blauvelt, Andrew ; Gordon, Kenneth B. ; Langley, Richard G....
Journal of Investigative Dermatology. , 2024

Link: https://doi.org/10.1016/..

7

Guselkumab Reduces Disease- and Mechanism-Related Biomarker..:

Blauvelt, Andrew ; Langley, Richard G. ; Branigan, Patrick J....
JID Innovations. 4 (2024) 5 - p. 100287 , 2024

Link: https://doi.org/10.1016/..

8

Matching-adjusted indirect comparison of guselkumab versus ..:

Langley, Richard G. ; Sanyal, Chiranjeev ; Situ, Aaron...
JAAD International. 15 (2024) - p. 165-167 , 2024

Link: https://doi.org/10.1016/..

9

Rapid and sustained improvements in itch and quality of lif..:

Magnolo, Nina ; Cameron, Michael C. ; Shahriari, Mona...
Journal of Dermatological Treatment. 35 (2024) 1 - p. , 2024

Link: https://doi.org/10.1080/..

10

Differential Pharmacodynamic Effects on Psoriatic biomarker..:

Blauvelt, Andrew ; Chen, Yanqing ; Branigan, Patrick J....
JID Innovations. , 2024

Link: https://doi.org/10.1016/..

11

Safety of Tralokinumab for the Treatment of Atopic Dermatit..:

Reich, Kristian ; Langley, Richard G. ; Silvestre, Juan Francisco...
SKIN The Journal of Cutaneous Medicine. 8 (2024) 2 - p. s375 , 2024

Link: https://doi.org/10.25251..

12

Orismilast in moderate-to-severe psoriasis: Efficacy and sa..:

Warren, Richard B. ; French, Lars E. ; Blauvelt, Andrew...
Journal of the American Academy of Dermatology. 90 (2024) 3 - p. 494-503 , 2024

Link: https://doi.org/10.1016/..

13

Effectiveness and safety of secukinumab updosing in patient..:

Papp, Kim A. ; Gooderham, Melinda ; Lynde, Charles...
Archives of Dermatological Research. 316 (2024) 7 - p. , 2024

Link: https://doi.org/10.1007/..

14

Continuous Tralokinumab Treatment over 4 Years in Adults wi..:

Blauvelt, Andrew ; Langley, Richard G. ; Peris, Ketty...
SKIN The Journal of Cutaneous Medicine. 8 (2024) 2 - p. s376 , 2024

Link: https://doi.org/10.25251..

15

44134 Long-Term Improvement in Difficult-To-Treat Areas and..:

Elewski, Boni ; Rich, Phoebe ; Langley, Richard G....
Journal of the American Academy of Dermatology. 89 (2023) 3 - p. AB190 , 2023

Link: https://doi.org/10.1016/..